Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the domestic market, contract testing services and sales of related products performed well, while in overseas markets, U.S. pharmaceutical companies, the company's major customers, continued to restrain research and development budgets, resulting in the loss of several anticipated contract testing projects.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥558 million (YoY -26.1%) |
| Operating profit | ¥-119 million |
| Ordinary income | ¥-120 million |
| Profit attributable to owners of the parent | ¥-123 million |
| Net income per share | -¥30.36 |
| Equity ratio | End of the current fiscal period 71.1 / End of previous period 70.2 |
| Total assets | ¥1,986 million |
| Net assets | ¥1,425 million |
| Cash flows from operating activities | ¥-121,468 thousand |
| Cash flows from investing activities | ¥-4,043 thousand |
| Cash flows from financing activities | ¥-55,880 thousand |
| Cash and cash equivalents at end of period | ¥960,023 thousand |
| Full-year earnings forecast | Net Sales ¥1,416 million (YoY -9.5%) / Operating profit ¥20 million (YoY -74.7%) / Ordinary income ¥25 million (YoY -80.6%) / Net income ¥19 million (YoY -84.5%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥1,416 million / Operating profit Not disclosed → ¥20 million / Ordinary income Not disclosed → ¥25 million / Net income Not disclosed → ¥19 million |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Regional sales | Pharmacological efficacy studies Domestic ¥12,467 thousand / Overseas ¥782 thousand / Safety and related studies Domestic ¥214,743 thousand / Overseas ¥330,925 thousand |
| Orders received and order backlog | Orders received ¥293,195 thousand / Order backlog ¥567,771 thousand |
| Depreciation and amortization | ¥17,018 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of stock acquisition rights ¥256 thousand / Extraordinary loss Loss on disposal of non-current assets ¥39 thousand |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Material subsequent events | None |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 4,076,933 shares |
| Treasury Shares at Period-End | 6,737 shares |
| Factors Behind Changes in Business Performance | In the domestic market, contract testing services and sales of related products performed well, while in overseas markets, U.S. pharmaceutical companies, the company's major customers, continued to restrain research and development budgets, resulting in the loss of several anticipated contract testing projects. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the domestic market, contract testing services and sales of related products performed well. In overseas markets, however, U.S. pharmaceutical companies, the company's major customers, continued to restrain research and development budgets, resulting in the loss of several anticipated contract testing projects. The increase in domestic revenue did not offset the decline in overseas revenue, and although the company reduced cost of sales, selling expenses and general and administrative expenses, the decline in revenue affected operating loss.